期刊
EUROPEAN UROLOGY
卷 57, 期 4, 页码 655-660出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.eururo.2009.09.037
关键词
Non-muscle invasive bladder cancer; Intravesical therapy; Fluorescent cystoscopy; BCG; Mitomycin C
资金
- Dutch Cancer Society [UU 2007-3922]
Background: Photodynamic diagnosis (PDD) is a technique that enhances the detection of occult bladder tumors during cystoscopy using a fluorescent dye. Objective: To study the differential effects of bacillus Calmette-Guerin (BCG) and mitomycin C (MMC) intravesical therapy on the false-positive rate of PDD of bladder cancer. Design, setting, and participants: This study included 552 procedures and 1874 biopsies. Intervention: Tumors were resected and biopsies were taken from suspicious areas, under guidance of white-light endoscopy and 5-ALA (5-aminolevulinic acid)-induced fluorescence cystoscopy. Measurements: The influence of intravesical BCG immunotherapy and intravesical MMC chemotherapy on pyuria, inflammation, and PDD specificity was examined in univariate analyses. Results and limitations: BCG significantly results in inflammation (odds ratio [OR]: 1.53, p = 0.002), leukocyturia (OR: 1.84, p = 0.034), and false positives in PDD (OR: 1.49, p = 0.001). However, a single BCG instillation within 3 mo before PDD is most likely not associated with increased false-positive rates (OR: 0.35, p = 0.26). Leukocyturia normalizes within 6 wk after the last BCG instillation, but PDD specificity is reduced up to 3 mo. Conclusions: BCG is an important predictor for false positives in PDD (5-ALA). More than one BCG instillation within 3 mo before fluorescence cystoscopy decreases the specificity of PDD. (C) 2009 European Association of Urology. Published by Elsevier B. V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据